Brolucizumab
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).[7][8] Brolucizumab successfully completed phase III development in wet age-related macular degeneration (AMD) meeting the primary efficacy endpoint of non-inferiority to aflibercept in mean change in best corrected visual acuity (BCVA) from baseline to week 48.Furthermore, brolucizumab demonstrated superiority to aflibercept in key secondary endpoint measures of disease activity in wet age-related macular degeneration, a leading cause of blindness in two head-to-head pivotal Phase III studies.[9][10][11][12] In October 2019, Novartis announced that the US Food and Drug Administration (FDA) approved brolucizumab injection for the treatment of wet age-related macular degeneration.[16][17] In June 2020, the FDA approved an updated prescription label for brolucizumab that included additional safety information—specifically including the characterization of adverse events, retinal vasculitis and retinal vascular occlusion, as part of the spectrum of intraocular inflammation observed in HAWK (NCT02307682)[11] and HARRIER (NCT02434328)[12] clinical trials and noted in the original prescribing information.